203Pb-DOTA-VMT-MCR1 (203Pb-VMT01) and the therapeutic analogue 212Pb-VMT01 are labeled peptides that bind with high affinity and specificity to MCR1. They are developed for targeted imaging and image-guided therapy of metastatic melanoma by the US Company Viewpoint Molecular Targeting, LLC in partnership with RadioMedix.
For imaging purpose, the company is also developing the analogue 68Ga-VMT02.
203Pb-DOTA-VMT-MCR1 binds with high affinity and specificity to melanocortin receptor subtype I (MC1R) and can be used for targeted imaging and image-guided therapy of metastatic melanomas. MC1R is upregulated at the surface of metastatic melanoma cells. A phase I study was initiated in May 2021.
Leading Emitter: alpha particle (α)